Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel.
Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel.
复制标题
DOI：
10.3389/fimmu.2020.614086
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Somech R
中科院分区：
文献类型：
--
作者：
Marcus N;Frizinsky S;Hagin D;Ovadia A;Hanna S;Farkash M;Maoz-Segal R;Agmon-Levin N;Broides A;Nahum A;Rosenberg E;Kuperman AA;Dinur-Schejter Y;Berkun Y;Toker O;Goldberg S;Confino-Cohen R;Scheuerman O;Badarneh B;Epstein-Rigbi N;Etzioni A;Dalal I;Somech R
在过去的几个月里，世界目睹了一场全球大流行，原因是严重急性呼吸综合征-冠状病毒-2(SARS-CoV-2)感染导致冠状病毒病2019年(新冠肺炎)。显然，这场大流行对个人的影响是不同的，对被认为是高危人群的影响很大。其中一个这样的人群被认为是患有涉及免疫系统组件或途径的初级遗传缺陷的患者。虽然人类对新冠肺炎的免疫力还不完全清楚，但到目前为止，有充分的证据表明，适应性细胞和先天细胞在抵御SARS-CoV-2病毒的保护中发挥着关键作用。在这里，我们的目的是总结以色列原发免疫缺陷患者的临床和实验室数据，这些患者的SARS-CoV-2检测呈阳性，以评估新冠肺炎对这些患者的影响。数据收集于2月中旬至9月底。在此期间，以色列经历了两波“新冠肺炎”病；第一波是从2月中旬到5月中旬，第二波是从6月中旬开始，到数据收集结束时仍在继续。在第二波疫情中，共有20名4个月至60岁的盆腔炎患者的SARS-CoV-2检测呈阳性，除一人外，其余患者均被检测到。在病毒检测时，14名患者正在接受每月例行的IVIG替代治疗。没有患者表现出严重的疾病，也没有患者需要住院；此外，7/20的患者完全没有症状。我们观察到新冠肺炎大流行对我们的PID患者的临床影响微乎其微，可能的解释包括高度的意识、额外的预防措施，甚至自我隔离。也有可能的是，只有特定的免疫途径(例如，I型干扰素信号)可能会增加更严重病程的风险，而这些途径在许多PID患者中不受影响。在某些情况下，缺乏免疫反应实际上可能是防止新冠肺炎后遗症发展的一种保护措施。
In the last few months the world has witnessed a global pandemic due to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19). Obviously, this pandemic affected individuals differently, with a significant impact on populations considered to be at high-risk. One such population, was assumed to be patients with primary genetic defect involving components or pathways of the immune system. While human immunity against COVID-19 is not fully understood, it is, so far, well documented, that both adaptive and innate cells have a critical role in protection against SARS-CoV-2. Here, we aimed to summarize the clinical and laboratory data on primary immunodeficiency (PID) patients in Israel, who were tested positive for SARS-CoV-2, in order to estimate the impact of COVID-19 on such patients. Data was collected from mid-February to end-September. During this time Israel experienced two “waves” of COVID-19 diseases; the first, from mid-February to mid-May and the second from mid-June and still ongoing at the end of data collection. A total of 20 PID patients, aged 4 months to 60 years, were tested positive for SARS-CoV-2, all but one, were detected during the second wave. Fourteen of the patients were on routine monthly IVIG replacement therapy at the time of virus detection. None of the patients displayed severe illness and none required hospitalization; moreover, 7/20 patients were completely asymptomatic. Possible explanations for the minimal clinical impact of COVID-19 pandemic observed in our PID patients include high level of awareness, extra-precautions, and even self-isolation. It is also possible that only specific immune pathways (e.g. type I interferon signaling), may increase the risk for a more severe course of disease and these are not affected in many of the PID patients. In some cases, lack of an immune response actually may be a protective measure against the development of COVID-19 sequelae.
登录
查看更多内容
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
9.1
作者：
Tangye, Stuart G.;Al-Herz, Waleed;Sullivan, Kathleen E.
通讯作者：
Sullivan, Kathleen E.
影响因子：
120.7
作者：
Kwan, Antonia;Abraham, Roshini S.;Puck, Jennifer M.
通讯作者：
Puck, Jennifer M.
DOI：
10.1016/j.jaci.2020.09.010
发表时间：
2021-03
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
Meyts I;Bucciol G;Quinti I;Neven B;Fischer A;Seoane E;Lopez-Granados E;Gianelli C;Robles-Marhuenda A;Jeandel PY;Paillard C;Sankaran VG;Demirdag YY;Lougaris V;Aiuti A;Plebani A;Milito C;Dalm VA;Guevara-Hoyer K;Sánchez-Ramón S;Bezrodnik L;Barzaghi F;Gonzalez-Granado LI;Hayman GR;Uzel G;Mendonça LO;Agostini C;Spadaro G;Badolato R;Soresina A;Vermeulen F;Bosteels C;Lambrecht BN;Keller M;Mustillo PJ;Abraham RS;Gupta S;Ozen A;Karakoc-Aydiner E;Baris S;Freeman AF;Yamazaki-Nakashimada M;Scheffler-Mendoza S;Espinosa-Padilla S;Gennery AR;Jolles S;Espinosa Y;Poli MC;Fieschi C;Hauck F;Cunningham-Rundles C;Mahlaoui N;IUIS Committee of Inborn Errors of Immunity;Warnatz K;Sullivan KE;Tangye SG
通讯作者：
Tangye SG
影响因子：
14.2
作者：
Quinti, Isabella;Lougaris, Vassilios;Plebani, Alessandro
通讯作者：
Plebani, Alessandro